All In Biotech

Drug Trial Radar · NCT05668403

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Mar 2, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
First posted
Dec 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Conditions

  • Primary Membranous Nephropathy

Interventions

  • B007Drug

    Drug: B007 injection Drug: Placebo injection

  • B007Drug

    Drug: B007 injection Drug: Placebo injection

  • B007Drug

    Drug: B007 injection Drug: Placebo injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity(DLT)Time frame: Approximately 1 years
  2. Security: Incidence of Treatment-Emergent Adverse EventsTime frame: Approximately 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking university first hospital

    Beijing, China · Recruiting

  • Longhua Hospital Shanghai University of Traditional Chinese Medicine

    Shanghai, China · Recruiting

  • Longhua Hospital Shanghai University of Traditional Chinese Medicine

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, He'nan, China · Recruiting

  • Hebei General Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • The First Affiliated Hospital,College of Medicine,Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.